CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Quality Chemical Industries Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Quality Chemical Industries Ltd
Plot 1-7
1st Ring Road, Luzira Industrial Park,
Phone: +256 312341100p:+256 312341100 KAMPALA, Uganda Ticker: CQCILCQCIL
Business Summary
Quality Chemical Industries Limited, formerly Cipla Quality Chemical Industries Limited, is a pharmaceutical manufacturer. The Company is engaged in manufacturing and selling pharmaceutical drugs with emphasis on antiretroviral (ARVs) and Artemisinin-based Combination Therapy (ACTs). It manufactures ACTs and hepatitis medicines to treat human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome, malaria and hepatitis. It offers three-in-one fixed-dose combination to fight AIDS. Its HIV product portfolio includes Lamivudine and Zidovudine Tablets, Efavirenz Tablets, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, and Lamivudine, Zidovudine and Nevirapine Tablets. Its antimalarials product portfolio includes Artemether + Lumefantrine tablets. Its hepatitis product portfolio includes Entecavir tablets and Tenofovir disoproxil fumarate tablets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman, Co-Founder EmmanuelKatongole 57 11/1/2013
Chief Executive Officer, Executive Director Nevin J.Bradford 62 11/26/2013
Chief Commercial Officer, Executive Director, Co-Founder George W.Baguma 59
12 additional Officers and Directors records available in full report.

General Information
Number of Employees: 320 (As of 3/31/2021)
Outstanding Shares: 3,651,909,200 (As of 3/31/2023)
Shareholders: 2,581
Stock Exchange: UGA
Fax Number: +256 414221319


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024